Close

Raptiva

Use of Raptiva Linked to Fatal Condition

Raptiva (efalizumab) was prescribed to treat psoriasis. In April 2009, drug manufacturer Genentech announced a withdrawal of the medication from the U.S. market due to health risks. Reports linked Raptiva to a disease known as progressive multifocal leukoencephalopathy (PML), a rare, but serious and most often fatal brain infection. No known cure or treatment for this disease exists.

Symptoms of PML that are linked to consumer use of Raptiva include:

  • Unusual Weakness
  • Loss of Coordination
  • Changes in Vision
  • Slurred or Difficulty Speaking
  • Cognitive Deterioration
  • Personality Changes

Other serious side effects linked to Raptiva include viral meningitis, sepsis infection of the kidneys or lungs, lymphoma (cancer of the lymph nodes).

How a Raptiva Side Effects Lawyer Can Help You

If you or a loved one suffered serious side effects after using Raptiva, you may be entitled to compensation for pain and suffering, lost wages, medical expenses and possibly other damages. An experienced Raptiva injury attorney at the Law Office of Jeff Martin can help you seek justice. Get in touch with us today.

Raptiva, which is administered by injection, was manufactured to suppress the T-cells, which left untreated in patients, results in inflamed skin patches associated with psoriasis. Some patients, however, suffered a depressed immune system that made them unable to fight off infections.

Contact a Raptiva Injury Lawyer in Oklahoma

If you or a loved one has been harmed or suffered serious side effects from taking Raptiva, contact our firm, serving Tulsa and communities throughout Oklahoma. When you choose the Law Office of Jeff Martin, you get an experienced lawyer who will work tirelessly to get you the compensation and justice you deserve. Take action today. Your initial consultation is free, and you don’t pay us unless you win.

  • Law Offices of Jeff Martin on Linked In
  • Law Offices of Jeff Martin on Linked In
  • Law Offices of Jeff Martin on Linked In